Wren Therapeutics, founded in 2016, is a University of Cambridge (UK) and Lund University (Sweden) spin-off company, based at the University of Cambridge. It is focused on drug discovery and development for protein misfolding diseases.
Last year, US funding giants from Boston and San Francisco led a $24 million Series A for the biopharma spin-out that is still to name its board.
Wren Therapeutics was set up by academics from St John's College in Cambridge to develop drugs to treat illnesses such as Alzheimer's, Parkinson’s and more than 50 other related diseases.
The fledgling business is spreading its wings by setting up a satellite office in Boston while remaining anchored within Cambridge University’s new Chemistry of Health Centre.
Wren raised the $24m cash from an international syndicate led by The Baupost Group in Boston with participation from San Francisco-based LifeForce Capital and a number of high net worth individual investors.
The Baupost Group is a long-only hedge fund founded in 1982 by Harvard Professor William Poorvu and partners and is the eighth-largest hedge fund by assets under management ($29.2bn).
Several of Wren’s scientific founders are members of St John’s, including Professor Sir Christopher Dobson, Master of St John's, Professor Tuomas Knowles, a St John's Fellow, and Dr Samuel Cohen, the St John’s Entrepreneur in Residence.
Wren Therapeutics focuses on drug discovery and development for protein misfolding diseases such as Alzheimer’s and Parkinson’s.